Kamada (KMDA) Depreciation & Amortization (CF) (2012 - 2026)
Kamada's (KMDA) quarterly Depreciation & Amortization (CF) came in at $3.9 million in Q2 2026, up 3.87% on a YoY basis from $3.7 million in Q2 2025, and up 1.04% quarter-over-quarter from $3.9 million in Q1 2026.
Analysis
Kamada (KMDA) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 3.87% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $15.3 million (up 4.11% YoY), and the FY2025 full-year result was $14.9 million, up 8.04% from the prior year.
- Depreciation & Amortization (CF) improved to $3.9 million in Q2 2026 per KMDA's latest filing, from $3.9 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $4.1 million in Q4 2024 and bottomed at $3.0 million in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $3.4 million across 5 years, with a median of $3.2 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 163.91% in 2022, then dropped 7.29% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $3.0 million in 2022, then advanced by 6.51% to $3.2 million in 2023, then advanced by 27.81% to $4.1 million in 2024, then decreased by 7.29% to $3.8 million in 2025, then gained by 2.37% to $3.9 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.9 million, $3.9 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 600,000.00 |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 3.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.89 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 3.21 Mn |
| Sep 30, 2023 | 3.18 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 3.01 Mn |
| Sep 30, 2022 | 3.06 Mn |
| Jun 30, 2022 | 3.06 Mn |
| Mar 31, 2022 | 3.03 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | 1.24 Mn |